That is exactly how it should be for Bios that have beneficial drugs in their pipeline. Good for the patients in the study and future generations that develop a need as well as investors. WIN WIN WIN situation with a high probability of success here in all the DD on the science here.
See 2016 as the make it year here and beyond as a hold on for a continued great ride.